Page last updated: 2024-11-04

temazepam and Parkinson Disease, Secondary

temazepam has been researched along with Parkinson Disease, Secondary in 1 studies

Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research Excerpts

ExcerptRelevanceReference
"Temazepam was consistently less potent than chlormethiazole on tests of drowsiness and psychomotor performance."2.67A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients. ( Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW, 1991)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tulloch, JA1
Ashwood, TJ1
Bateman, DN1
Woodhouse, KW1

Trials

1 trial available for temazepam and Parkinson Disease, Secondary

ArticleYear
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
    Age and ageing, 1991, Volume: 20, Issue:6

    Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Femal

1991